Forget Hong Kong, Grail is now going for a 2019 IPO in the US — Bloomberg
In testament to the murky sentiment hanging over the Hong Kong stock exchange — and hot on a record-breaking streak of public debuts stateside — high-flying cancer testing startup Grail has reportedly dropped its plans for a Hong Kong listing in favor of the US market.
Months after getting the scoop on Grail’s intention to list on the HKEX, Bloomberg is now reporting that Grail is mulling a US IPO instead, with a filing expected as early as 2019, citing unnamed sources.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.